Aptiom

Generic name: Eslicarbazepine
Drug class: Dibenzazepine anticonvulsants

Usage of Aptiom

Aptiom is an anticonvulsant. It works by decreasing nerve impulses that cause seizures and pain.

Aptiom is used alone or with other medications to treat partial-onset seizures in adults and children who are at least 4 years old.

Aptiom may also be used for purposes not listed in this medication guide.

Aptiom side effects

Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).

Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include: skin rash, fever, swollen glands, flu-like symptoms, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes. This reaction may occur several weeks after you began using eslicarbazepine.

Eslicarbazepine can reduce the sodium in your body to dangerously low levels, which can cause a life-threatening electrolyte imbalance. Call your doctor right away if you have nausea, lack of energy, confusion, feeling tired or irritable, severe weakness, muscle pain, or increased seizures.

Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, depression, anxiety, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.

Also call your doctor at once if you have:

  • severe dizziness or drowsiness, vision changes, thinking problems, trouble with walking or coordination;
  • sudden weakness or ill feeling, fever, chills, sore throat, mouth sores; or
  • liver problems - nausea, loss of appetite, upper stomach pain, dark urine, jaundice (yellowing of the skin or eyes).

    • Common Aptiom side effects may include:

  • dizziness, drowsiness, headache;
  • feeling tired;
  • nausea, vomiting;
  • coordination problems, feeling shaky; or
  • double vision.

    • This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Aptiom

    You should not use Aptiom if you are allergic to eslicarbazepine or oxcarbazepine.

    To make sure Aptiom is safe for you, tell your doctor if you have ever had:

  • kidney disease;
  • liver disease;
  • a blood cell disorder; or
  • mood problems or suicidal thoughts.

    • Some people have thoughts about suicide while taking an anticonvulsant. Your doctor will need to check your progress at regular visits while you are taking Aptiom. Your family or other caregivers should also be alert to changes in your mood or symptoms.

    Do not start or stop taking Aptiom during pregnancy without your doctor's advice. Having a seizure during pregnancy could harm both mother and baby. Tell your doctor right away if you become pregnant while taking Aptiom for seizures.

    If you are pregnant, your name may be listed on a pregnancy registry. This is to track the outcome of the pregnancy and to evaluate any effects of eslicarbazepine on the baby.

    Aptiom can make birth control pills less effective. Ask your doctor about using non hormonal birth control (condom, diaphragm with spermicide) to prevent pregnancy while taking Aptiom.

    Eslicarbazepine can pass into breast milk and may harm a nursing baby. You should not breast-feed while using this medicine.

    Aptiom not approved for use by anyone younger than 18 years old.

    Relate drugs

    How to use Aptiom

    Usual Adult Dose of Aptiom for Epilepsy:

    Monotherapy and Adjunctive Therapy: -Initial dose: 400 mg orally once a day; some patients may be initiated at 800 mg orally once a day if the need for seizure reduction outweighs an increased risk of adverse reactions -Dose titration: Increase dosage by 400 to 600 mg weekly, based on response and tolerability -Maintenance dose: 800 to 1600 mg orally once a day; for patients on monotherapy, the 800 mg once daily maintenance dose should be considered in patients who are unable to tolerate a 1200 mg daily dose; for patients on adjunctive therapy, the 1600 mg daily dose should be considered in patients who did not achieve a satisfactory response with a 1200 mg daily dose Comments: -This drug may be taken without regard to meals. -Tablets may be swallowed whole or crushed. Use: For the treatment of partial-onset seizures as monotherapy or adjunctive therapy

    Usual Adult Dose of Aptiom for Seizures:

    Monotherapy and Adjunctive Therapy: -Initial dose: 400 mg orally once a day; some patients may be initiated at 800 mg orally once a day if the need for seizure reduction outweighs an increased risk of adverse reactions -Dose titration: Increase dosage by 400 to 600 mg weekly, based on response and tolerability -Maintenance dose: 800 to 1600 mg orally once a day; for patients on monotherapy, the 800 mg once daily maintenance dose should be considered in patients who are unable to tolerate a 1200 mg daily dose; for patients on adjunctive therapy, the 1600 mg daily dose should be considered in patients who did not achieve a satisfactory response with a 1200 mg daily dose Comments: -This drug may be taken without regard to meals. -Tablets may be swallowed whole or crushed. Use: For the treatment of partial-onset seizures as monotherapy or adjunctive therapy

    Usual Pediatric Dose of Aptiom for Epilepsy:

    4 to less than 18 years: Monotherapy and Adjunctive Therapy: 11 to 21 kg: -Initial dose: 200 mg orally once a day; increase once a week in increments of no more than 200 mg, based on tolerability and response -Maintenance dose: 400 to 600 mg orally once a day -Maximum dose: 600 mg orally once a day 22 to 31 kg: -Initial dose: 300 mg orally once a day; increase once a week in increments of no more than 300 mg, based on tolerability and response -Maintenance dose: 500 to 800 mg orally once a day -Maximum dose: 800 mg orally once a day 32 to 38 kg: -Initial dose: 300 mg orally once a day; increase once a week in increments of no more than 300 mg, based on tolerability and response -Maintenance dose: 600 to 900 mg orally once a day -Maximum dose: 900 mg orally once a day Greater than 38 kg: -Initial dose: 400 mg orally once a day; increase once a week in increments of no more than 400 mg, based on tolerability and response -Maintenance dose: 800 to 1200 mg orally once a day -Maximum dose: 1200 mg orally once a day Comments: -This drug may be taken without regard to meals. -Tablets may be swallowed whole or crushed. Use: For the treatment of partial-onset seizures in patients 4 years of age and older

    Usual Pediatric Dose of Aptiom for Seizures:

    4 to less than 18 years: Monotherapy and Adjunctive Therapy: 11 to 21 kg: -Initial dose: 200 mg orally once a day; increase once a week in increments of no more than 200 mg, based on tolerability and response -Maintenance dose: 400 to 600 mg orally once a day -Maximum dose: 600 mg orally once a day 22 to 31 kg: -Initial dose: 300 mg orally once a day; increase once a week in increments of no more than 300 mg, based on tolerability and response -Maintenance dose: 500 to 800 mg orally once a day -Maximum dose: 800 mg orally once a day 32 to 38 kg: -Initial dose: 300 mg orally once a day; increase once a week in increments of no more than 300 mg, based on tolerability and response -Maintenance dose: 600 to 900 mg orally once a day -Maximum dose: 900 mg orally once a day Greater than 38 kg: -Initial dose: 400 mg orally once a day; increase once a week in increments of no more than 400 mg, based on tolerability and response -Maintenance dose: 800 to 1200 mg orally once a day -Maximum dose: 1200 mg orally once a day Comments: -This drug may be taken without regard to meals. -Tablets may be swallowed whole or crushed. Use: For the treatment of partial-onset seizures in patients 4 years of age and older

    Warnings

    Do not stop using Aptiom suddenly.

    Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include: skin rash, fever, swollen glands, flu-like symptoms, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes. This reaction may occur several weeks after you began using Aptiom.

    Call your doctor right away if you have symptoms of low sodium levels in your body such as nausea, confusion, severe weakness, muscle pain, or increased seizures.

    Some people have thoughts about suicide while taking seizure medicine. Stay alert to changes in your mood or symptoms. Report any new or worsening symptoms to your doctor.

    What other drugs will affect Aptiom

    Tell your doctor about all your current medicines and any you start or stop using, especially:

  • all other seizure medicines you use;
  • omeprazole; or
  • rosuvastatin (Crestor) or simvastatin (Zocor).

    • This list is not complete. Other drugs may interact with eslicarbazepine, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

    Popular FAQ

    Aptiom (eslicarbazepine) is a once-daily seizure medicine (anticonvulsant) used alone or with other medicines to treat focal (partial-onset) seizures in patients 4 years of age and older. When used alone, it can be started in patients who newly start therapy, or in patients who change from other seizure drugs to Aptiom.

    No, Aptiom has not been reported to cause weight gain or weight loss in clinical studies. In general weight changes can be common with other seizure medicines used to treat epilepsy. Aptiom may cause nausea, vomiting or liver problems which may reduce your appetite. Report any weight changes to your doctor. Felbamate, topiramate, and zonisamide are associated with weight loss and gabapentin, pregabalin, valproic acid, and vigabatrin are reported to cause weight gain. Lamotrigine, levetiracetam, and phenytoin are more weight neutral.

    Eslicarbazepine, the active ingredient in Aptiom, can stay in your system from 2.5 to 4 days after your last dose, based on a half-life of 13 to 20 hours. The half-life is the time it takes for half of the drug to be broken down and excreted from your body. It usually takes 5 half-lives for a drug to be fully cleared from your body, but this can vary based on age, weight, genetics, your medical conditions, or other medicines you take.

    Some doctors may prescribe Aptiom (eslicarbazepine) “off-label” for nerve pain, meaning it may be prescribed for a use not specifically approved by the FDA or listed in package labeling. However, a 2019 literature review found that there was not enough evidence to recommend the use of the anticonvulsant Aptiom for nerve pain.

    Aptiom (eslicarbazepine) is a prescription medicine used to treat focal seizures (also called partial-onset seizures) associated with epilepsy in adults and children 4 years of age and older. Aptiom can be used alone or with other medicines for the treatment of seizures. It is given as an oral tablet once daily.

    A generic product for Aptiom, known as eslicarbazepine, has been approved by the FDA. Ask your pharmacist about the availability of eslicarbazepine from your pharmacy. The FDA first approved Aptiom, an anti-seizure medicine from Sunovion Pharmaceuticals, in November 2013. The first generic, from Dr. Reddy’s Lab, was initially approved in June 2021.

    In one physical dependence study with Aptiom, there was evidence of two withdrawal symptoms, anxiety and nausea, in volunteers who took a daily dose of 800 mg Aptiom for 4 weeks prior to discontinuation when compared to the placebo group. Do not stop taking Aptiom without talking to your healthcare provider. Stopping Aptiom suddenly can cause serious problems, including seizures that will not stop (status epilepticus).

    Aptiom (eslicarbazepine) is a once-daily oral seizure medicine (anticonvulsant) used alone or with other medicines to treat focal seizures (formerly called partial seizures). Keppra (levetiracetam) is an oral seizure medicine used to treat focal seizures, but is additionally approved to treat myoclonic seizures and tonic-clonic seizures. It is usually given twice a day. Both prescription treatments are used to treat adults and children of various ages with epilepsy. Continue reading

    Aptiom (eslicarbazepine) is a once-daily seizure medicine (anticonvulsant) used alone or with other medicines to treat focal (partial-onset) seizures in patients 4 years of age and older. When used alone, it can be started in patients who newly start therapy, or in patients who change from other seizure drugs to Aptiom.

    No, Aptiom has not been reported to cause weight gain or weight loss in clinical studies. In general weight changes can be common with other seizure medicines used to treat epilepsy. Aptiom may cause nausea, vomiting or liver problems which may reduce your appetite. Report any weight changes to your doctor. Felbamate, topiramate, and zonisamide are associated with weight loss and gabapentin, pregabalin, valproic acid, and vigabatrin are reported to cause weight gain. Lamotrigine, levetiracetam, and phenytoin are more weight neutral.

    Eslicarbazepine, the active ingredient in Aptiom, can stay in your system from 2.5 to 4 days after your last dose, based on a half-life of 13 to 20 hours. The half-life is the time it takes for half of the drug to be broken down and excreted from your body. It usually takes 5 half-lives for a drug to be fully cleared from your body, but this can vary based on age, weight, genetics, your medical conditions, or other medicines you take.

    Some doctors may prescribe Aptiom (eslicarbazepine) “off-label” for nerve pain, meaning it may be prescribed for a use not specifically approved by the FDA or listed in package labeling. However, a 2019 literature review found that there was not enough evidence to recommend the use of the anticonvulsant Aptiom for nerve pain.

    Aptiom (eslicarbazepine) is a prescription medicine used to treat focal seizures (also called partial-onset seizures) associated with epilepsy in adults and children 4 years of age and older. Aptiom can be used alone or with other medicines for the treatment of seizures. It is given as an oral tablet once daily.

    A generic product for Aptiom, known as eslicarbazepine, has been approved by the FDA. Ask your pharmacist about the availability of eslicarbazepine from your pharmacy. The FDA first approved Aptiom, an anti-seizure medicine from Sunovion Pharmaceuticals, in November 2013. The first generic, from Dr. Reddy’s Lab, was initially approved in June 2021.

    In one physical dependence study with Aptiom, there was evidence of two withdrawal symptoms, anxiety and nausea, in volunteers who took a daily dose of 800 mg Aptiom for 4 weeks prior to discontinuation when compared to the placebo group. Do not stop taking Aptiom without talking to your healthcare provider. Stopping Aptiom suddenly can cause serious problems, including seizures that will not stop (status epilepticus).

    Aptiom (eslicarbazepine) is a once-daily oral seizure medicine (anticonvulsant) used alone or with other medicines to treat focal seizures (formerly called partial seizures). Keppra (levetiracetam) is an oral seizure medicine used to treat focal seizures, but is additionally approved to treat myoclonic seizures and tonic-clonic seizures. It is usually given twice a day. Both prescription treatments are used to treat adults and children of various ages with epilepsy. Continue reading

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords